A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LAMOTRIGINE 200-400MG/DAY COMPARED WITH PLACEBO IN SUBJECTS WITH PAINFUL DIABETIC NEUROPATHY

Trial Profile

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LAMOTRIGINE 200-400MG/DAY COMPARED WITH PLACEBO IN SUBJECTS WITH PAINFUL DIABETIC NEUROPATHY

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2012

At a glance

  • Drugs Lamotrigine (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top